“…Furthermore, no evidence has been seen of significant improvement in productivity in patients with uncontrolled persistent asthma treated with biologics targeting IL-5. 23 In conclusion, patients with uncontrolled persistent asthma who do not respond to currently available therapies are in need of additional treatment options. This analysis demonstrates that dupilumab every 2 weeks regimens provide significant and clinically meaningful improvements in asthma control, asthma symptoms, and QoL and significantly improve workplace productivity.…”